<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2012071310267N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2012-09-16</date_registration>
      <primary_sponsor>Vice chancellor for research, Tehran University of Medical Science</primary_sponsor>
      <public_title>Evaluating Direct Current Stimulation effect on memory performance</public_title>
      <acronym></acronym>
      <scientific_title>Evaluating the effect of anodal transcranial Direct Current Stimulation on working memory performance in individuals with Mild Cognitive Impairment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2012-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>20</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/10731</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Crossover, Purpose: Treatment, Other design features: Randomization: Subjects assigned to different strata according to their education level. In each stratum, we use blocks with different size in order to prevent selection bias and the allocation ratio is 1:1. (Stratified block randomization)&#13;
Blinding: The person who implements the randomization and enrolls participants is blinded during allocation. All participants are also blinded about their final group. All data will be analyzed by a blind analyzer, who does not know which participant allocated to which group.                        &#13;
Trial design: Because in cross over trials, the therapeutic effects of two different modes of intervention (active tDCS versus sham tDCS) will be compared in each person with same characteristics, which is better than this comparison in two different persons with different characteristics, in this Randomized Controlled Clinical Trial, cross over design is chosen. Therefore, effects of confounding variables will be minimized and fewer biases will threaten study results.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Mild cognitive disorder.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group: Transcranial Direct Current Stimulation is a non-invasive and non-convulsive technique with high safety rate and low side-effect incidence. It can modulate cortical excitability in target region of the brain, so that anodal and cathodal tDCS would increase and decrease cortical excitability, respectively. According to “10-20 international system for EEG electrode placement” the anode will be placed on F3 (left DLPFC) , while the cathode would be locate on contralateral (right) supraorbital region. Electrodes (35cm2) will be inserted in saline soaked sponges. These sponges will be washed from participant to participant, to avoid further saline concentrating. Each person in case group receives 1 mA current for 20 minutes. Intervention 2: Control Group: Electrodes will be fixed on subject's head for 20 minutes. In sham group, the current reach the maximum dose (1mA) gradually, then cut off. This help participants feel the initial tingling and so remain blind during previously mentioned 20 minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Masoud Mehrpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Firoozgar Hospital, Beh Afarin Street, Karimkhan zand Street, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8214 1600</telephone>
        <email>m-mehrpour@tums.ac.ir; fgowhari@gmail.com</email>
        <affiliation>Firoozgar Hospital, Tehran University of Medical Science</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Masoud Mehrpour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Firoozgar Hospital, Beh Afarin Street, Karimkhan zand Street, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 8214 1600</telephone>
        <email>m-mehrpour@tums.ac.ir; fgowhari@gmail.com</email>
        <affiliation>Firoozgar Clinical Research Development Center, Tehran University of Medical Science</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: Twenty volunteers with diagnosed MCI according to Peterson’s criteria will be recruited. None of them must have any neurological, physical, or other life threatening disease. All the subjects are right-handed and non-pregnant.&#13;
Exclusion criteria: Lost to follow up</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F06.7</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Mild cognitive disorder</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: Transcranial Direct Current Stimulation is a non-invasive and non-convulsive technique with high safety rate and low side-effect incidence. It can modulate cortical excitability in target region of the brain, so that anodal and cathodal tDCS would increase and decrease cortical excitability, respectively. According to “10-20 international system for EEG electrode placement” the anode will be placed on F3 (left DLPFC) , while the cathode would be locate on contralateral (right) supraorbital region. Electrodes (35cm2) will be inserted in saline soaked sponges. These sponges will be washed from participant to participant, to avoid further saline concentrating. Each person in case group receives 1 mA current for 20 minutes.</i_keyword>
      <i_keyword>Control Group: Electrodes will be fixed on subject's head for 20 minutes. In sham group, the current reach the maximum dose (1mA) gradually, then cut off. This help participants feel the initial tingling and so remain blind during previously mentioned 20 minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Spatial Working Memory Score. Timepoint: at the beginning before the intervention, immediately after the first intervention session, immediately after the second intervention session. Method of measurement: CANTAB, executive function package, spatial working memory test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Mental State. Timepoint: at the beginning before the intervention. Method of measurement: Mini Mental State Examination (MMSE).</sec_outcome>
      <sec_outcome>Dementia rating. Timepoint: at the beginning before the intervention. Method of measurement: Clinical Dementia Rating (CDR) score.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for research, Tehran University of Medical Science</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-07-02</approval_date>
        <contact_name>Tehran University of Medical Science Ethic Committee</contact_name>
        <contact_address>Medical Ethic Resaerch Center, Tehran University of Medical Science, 16th Azar Street, Keshavarz Blvd., Tehran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
